Reported results
- Third quarter reported net revenues of $3.10 billion.
- Third quarter reported diluted EPS of $2.78.
- Third quarter adjusted diluted EPS of $3.00.
- Third quarter reported operating income of $479 million.
- Third quarter adjusted operating income of $517 million.
- Third quarter reported net income attributable to Quest Diagnostics of $312 million.
Guidance
- Full year 2026 net revenues expected to be between $12.065 billion and $12.105 billion.
- Full year 2026 reported diluted EPS expected to be between $10.21 and $10.31.
- Full year 2026 adjusted diluted EPS expected to be between $11.25 and $11.35.
- Full year 2026 cash provided by operations expected to be approximately $1.90 billion.
- Full year 2026 capital expenditures expected to be approximately $550 million.
Price and volatility reaction
The stock moved +1.8% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -9.3 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 238.93 | 2026-10-21 |
| Close after release | 243.28 | 2026-10-22 |
| Realised move | +1.8% | close to close |
| 30d ATM IV change | -9.3 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-22 (8-K, Item 2.02). Read the original filing on sec.gov.
